UBS AM’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

UBS AM’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-39,422	Closed	-$1.13M	–	2732
2023 Q2	$1.13M	Hold	39,422	–	–	﹤0.01%	1943
2023 Q1	$1.13M	Buy	39,422 +9,465	+32%	+$280K	﹤0.01%	1943
2022 Q4	$935K	Buy	+29,957	New	+$977K	﹤0.01%	1879

UBS AM's DICE Position: Q3 2023 in Review

UBS AM sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 39,422 shares — an estimated $1.13M sold.

UBS AM first reported a position in DICE in Q4 2022 and held it in 3 quarters. The position peaked at $1.13M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

UBS AM reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS AM sold 39,422 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.13M.
UBS AM first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
UBS AM's DICE Therapeutics, Inc. Common Stock position peaked at $1.13M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.